The present invention relates generally to the modification of a left atrial appendage and, more specifically, to devices, systems and methods for occluding or otherwise structurally altering such appendages.
The left atrial appendage is a feature of all human hearts. The upper chambers of the heart, the atria, have this appendage attached to each of them. The physiologic function of such appendages is not completely understood, but they do act as a filling reservoir during the normal pumping of the heart. The appendages typically protrude from the atria and cover an external portion of the atria. Atrial appendages differ substantially from one to another. For example, one atrial appendage may be configured as a tapered protrusion while another atrial appendage may be configured as a re-entrant, sock-like hole. The inner surface of an appendage is conventionally trabeculated with cords of muscular cardiac tissue traversing its surface.
The atrial appendages are inert while blood is being pumped through them during normal heart function. In other words, the appendages don't have a noticeable effect on blood pumped through them during normal heart function. However, in cases of atrial fibrillation, when the atria go into arrhythmia, blood may pool and thrombose inside of the appendages. Among other things, this can pose a stroke risk when it occurs in the left appendage since the thrombus may be pumped out of the heart and into the cranial circulation.
Historically, appendages have sometimes been modified surgically to reduce the risk imposed by atrial fibrillation. In recent years devices which may be delivered percutaneously into the left atrial appendage have been introduced. The basic function of these devices is to exclude the volume within the appendage with an implant which then allows blood within the appendage to safely thrombose and then to be gradually incorporated into cardiac tissue. This can leave a smooth, endothelialized surface where the appendage used to be.
Embodiments of the present invention include percutaneously delivered implants or medical devices designed to exclude or modify the inner surface of the left atrial appendage to reduce the risk of stroke during atrial fibrillation. Embodiments of the present invention further include related methods and systems.
In accordance with one embodiment of the present invention, a medical device for modifying a left atrial appendage (LAA) is provided. The medical device includes a body formed of a self-expanding material. The body exhibits a textured surface including a plurality of protruding portions and a plurality of recesses. Each protruding portion is separated from an adjacent protruding portion by a recess of the plurality of recesses. In one embodiment, the body may exhibit a substantially spherical geometry. The body may be formed from a material that comprises, for example, a reticulated foam.
In accordance with another embodiment of the present invention, a medical device for modifying a left atrial appendage includes a mesh bag and at least one self-expanding body disposed within the mesh bag. The self-expanding body may include one or more foam bodies. The mesh bag may be formed of, for example, a material comprising at least one nylon, polyester or silicone. The self-expanding body or bodies may be formed of, for example, at least one of a polymer foam, polyurethane, and polyvinyl acetate.
In accordance with another embodiment of the present invention, a method of modifying a left atrial appendage is provided. The method includes providing a body formed of a self-expanding material, the body exhibiting a textured surface including a plurality of protruding portions and a plurality of recesses, wherein each protruding portion is separated from an adjacent protruding portion by a recess of the plurality of recesses. The body is compressed within a delivery vehicle and the delivery vehicle is positioned adjacent an opening of the LAA. The body is discharged from the delivery vehicle into the LAA and expanded such that the body engages a side wall of the LAA and substantially occludes an opening of the LAA.
In accordance with yet another embodiment of the present invention, another method is provided for modifying a left atrial appendage. The method includes disposing a mesh bag within the LAA and disposing at least one self-expanding body within an interior of the mesh bag. The mesh bag is securely closed to retain the at least one self-expanding body within the bag.
In another one embodiment, the medical device includes a first frame member, a second frame member, a spring member and a tissue in-growth member. The first and second frame members include a first and second flat configuration, respectively, and are non-coplanar with each other. The first frame member is configured to anchor within the left atrial appendage (LAA). The spring member is connected between the first and second frame members. The tissue in-growth member is attached to the second frame member and is configured to cover an opening of the LAA.
In a further embodiment, the medical device includes a frame member having a substantially flat configuration and includes distal anchor members for anchoring the frame member within the LAA. The medical device also includes a tissue in-growth member that is attached to the frame member and configured to cover an opening of the LAA.
In yet another embodiment, the medical device includes a frame member having an anchoring system that is configured to anchor the frame member at least partially within the LAA. The medical device also includes a tissue in-growth member that is attached to the frame member and is configured to prevent potential embolic material from escaping the LAA.
These and other aspects of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
The foregoing and other advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings in which:
Referring to
The anchor member 106 may be sized and configured to expand outward against a surface of a wall 112 of the LAA 102 so that upper and lower portions of the anchor member 106 extend to a dimension that is larger than the LAA opening 114. The anchor member 106 can be formed of, for example, a shape memory alloy such as Nitinol. Use of such a material enables the anchor member 106 to be delivered in a collapsed state and then self-expand upon deployment in the LAA 102. In another embodiment, the anchor member 106 may be configured to be manually expanded upon delivery to and deployment in the LAA 102. In one embodiment, a spring or biasing member 115 may be positioned within the anchor member 106 so as to pull opposing distal and proximal sides of the anchor member 106 towards one another such the upper and lower portions of the anchor member 106 are placed in, and maintained in, an expanded or extended position.
A plurality of tines 116, which may include, for example, posts or barbs, may be disposed on the anchor member 106. The tines 116 may be located and configured to “grab” or otherwise engage the LAA wall 112. With such an arrangement, the anchor member 106 is configured to be positioned and anchored within the LAA 102 to prevent migration of the medical device 100 out of the LAA 102. In one embodiment, the anchor member 106 may be substantially flat and planar. The anchor member 106 may also include a tissue in-growth member 118 associated therewith, such as a polymer substrate, or any suitable known member for promoting tissue growth. According to one aspect of the present invention, the tissue in-growth member can be a porous polymer member, such as a polymer based foam or fabric. In one embodiment, fabric may be disposed over the frame of the anchor member 106. In another embodiment a foam member may be disposed on or within the frame of the anchor member 106.
The cover member 110 is connected to the anchor member 106 via the biasing member 108. The cover member 110 may include a frame 120 sized and configured to be larger than the opening 114 of the LAA 102. The frame 120 can be configured to support a tissue in-growth member 122, such as a polymer substrate, or any suitable tissue promoting or enhancing member. Such tissue in-growth member 122 can be a porous member, such as reticulated foam, fabric or Dacron®, configured to hold blood cells and to promote and induce tissue growth. With the cover member 110 being coupled with the anchor member 106 via the biasing member 108, the cover member 110 can be configured to be biased against the left atrial wall 124 over the opening 114 of the LAA 102 via the biasing member 108 after the anchor member 106 is appropriately positioned and anchored within the LAA 102.
When deployed within the LAA 102, the medical device 100 covers or occludes the opening 114 of the LAA to seal off the LAA 102 from the left atria. Thus, if any embolic material exists within the LAA 102, the medical device 100 prevents such from leaving the LAA 102 and entering back into the left atria. Additionally, the medical device prevents further entry of blood into the LAA 102 and, thus, further preventing production of embolic material within the LAA.
Referring now to
The cover member 158 may be sized and configured to be biased or to sit against the LAA opening 114. Further, as with other embodiments, the cover member 158 is not limited to a polymer substrate, but may include any suitable tissue in-growth member known in the art. Additionally, with reference to
Referring now to
Referring now to
The anchor 192 includes a plurality of arms 192A-192D joined at a central hub 194. Along the length of each arm 192A-192D, tines 96 may extend therefrom and be oriented so that the medical device 190 is substantially prevented from migrating from the LAA 102 once it is disposed therein. The arms 192A-192D may each extend from the central hub 194 and self-expand when delivered to the LAA 102 in a manner such that each arm 192A-192D independently expands and biases against the LAA wall 112 to secure the medical device 112 within the LAA 112. A biasing member 199 may be coupled between the anchor 192 and the cover member 196 so as to bias the cover member 196 against the atrial wall 124 and more effectively cover or occlude the LAA opening 114.
Referring now to
Referring now to
The frame member 282 may be formed from, for example, a shape member alloy such as Nitinol, such that the frame member 282 may be disposed within a catheter 284 or other delivery vehicle in an undeployed (e.g., a lengthened, uncoiled) state. When deployed from the catheter 284 or other delivery vehicle, the frame member 282 expands to its coiled state such as shown
In another embodiment, and as shown in
Referring now to
It is also contemplated that the body 302 of the medical device 300, in another embodiment, can be formed without the plurality of protruding portions and recessed portions described above. In other words, the surface of the body 302 can be left relatively smooth or untextured in its substantially natural state of, for example, the foam material.
In one embodiment, the body may be a “solid” geometry meaning that the foam or other material extends through the body 302. In another embodiment, the body 302 may be substantially hollowed out or hollowed at one or more selected portions within the body 302. When hollowed out, the body 302 would be more compact when collapsed and carried by a catheter or other delivery vehicle. While the body 302 may exhibit other geometries (e.g., cylindrical, ovoid, elongated), the use of a spherical or substantially spherical geometry (referring to the overall shape and disregarding the textured surface) enables deployment of the medical device 300 within an LAA 102 (
In another embodiment, the foam or other material can include variations within portions of the body 302 such that various portions of the body may compact smaller than other portions of the body. Such can be employed, for example, by manipulating the number of pours per square inch in the material forming the body 302 so that the body exhibits a graded porosity. For example, for a spherical configuration, the central region of the foam body may include a different number of pours than the outer regions of the foam body so as to manipulate the compactive and expansive characteristics of the foam body. Additionally, or alternatively, one-half of the sphere may exhibit one level of porosity while the other half exhibits a different level of porosity. Similarly, along the length of any other shaped configuration, such as a conical or cylindrical configuration the level of porosity may change. Additionally, such changes in porosity may be gradual, or may be relatively abrupt.
Referring to
The textured surface of the body 302 may be tailored depending on a variety of factors. For example, the protruding portions 304 may be configured to effect increased engagement with the LAA wall 114 (
Referring briefly to
Referring now to
As will be appreciated by those of ordinary skill in the art, it is sometimes necessary to recapture the medical device 300 after deployment for purposes of repositioning the medical device within the LAA 102. In such a case, a tether 346 may be coupled to a plurality of ties 348 that circumscribe the body 302 of the medical device. The tether 346 and the web or cage formed by the ties 348 pull the medical device 300 back within the envelope defined by the radially expanded fingers 342 of the slotted sleeve 340. As the tether 346 and slotted sleeve 340 are drawn back in through the opening 344 of the catheter 310, the medical device 300 is returned to a collapsed state within the catheter 310 and may be redeployed into the LAA or removed completely from the patient. When the device 300 is satisfactorily position with the LAA 102, the tether may be disconnected from the ties 348.
In one embodiment, such ties 348 may be formed of a shape memory alloy, such as Nitinol, to assist in expansion of the medical device 300 in expanding when deployed in the LAA. The ties 348 may be disposed within recesses 306 of the medical device's textured surface. When deployed in an LAA 102, the ties 348 may remain with the body 302, although they may not be intended to serve any specific purpose in terms of anchoring the medical device 300 or promoting tissue growth. In another embodiment, instead of using ties 348 for recapture purposes, a mesh bag may be disposed about the body 302 of the medical device 300 in a manner similar to a further embodiment that is described hereinbelow.
In yet another embodiment, the slotted sleeve 340 need not be utilized. Instead, a pusher element (e.g., a rod or other device) may be inserted through the body 302 and configured to engage the distal end of the body 302. When it is desired to recapture the medical device 300, the pusher element may push against the distal end of the body while the ties are pulled toward the catheter 310 to effect an elongation (and a corresponding radial contraction) of the body 302. The medical device may then be drawn back within the catheter 310.
Referring now to
In yet another embodiment, the protrusions 304 in the contact surface areas 350 may exhibit similar geometric configurations as the rest of the texture surface of the body 302. However, the surface areas not in contact with delivery vehicle (referred to as delivery non-contact surface indicated by reference numerals 352) may be modified by stiffening the material or further roughening the surface of the protrusions 304. For example, such delivery non-contact areas may be coated or metalized, such as with graphite, to stiffen the protrusions 304 and provide a roughened surface area. These coated areas then provide improved engagement of the medical device 300 with the LAA wall 114 (
Referring now to
Use of a mesh bag 362 and multiple self-expanding bodies 364 again provides ease of use for the doctor deploying the medical device due to the fact that deployment is relatively insensitive to the approach angle of the catheter 366. Additionally, the use of multiple smaller expanding bodies 364 makes it more likely to substantially fill the LAA 102 in a generally conformal manner.
Various other features may be included in any of the above described embodiments. For example, radio opaque markers may be associated with any of a variety of components of the described medical devices to facilitate monitoring of the deployment and positioning of the medical device. Additionally, various materials may be used including bioresorbant materials for certain components. Further, various components may be coated to effect a desired biological reaction as will be appreciated by those of ordinary skill in the art.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description.
This application claims the benefit of United States Provisional Patent Application Ser. No. 60/981,451, filed Oct. 19, 2007, entitled MEDICAL DEVICE FOR MODIFICATION OF LEFT ATRIAL APPENDAGE, the disclosure of which is incorporated by reference herein in its entirety. This application also claims the benefit of United States Provisional application Ser. No. 61/047,058 filed Apr. 22, 2008 entitled DEVICE AND SYSTEM FOR ANEURYSM EMBOLIZATION, the disclosure of which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3095877 | Rowan | Jul 1963 | A |
3874388 | King et al. | Apr 1975 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5284488 | Sideris | Feb 1994 | A |
5334217 | Das | Aug 1994 | A |
5425733 | Schmieding | Jun 1995 | A |
5425740 | Hutchinson, Jr. | Jun 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5861003 | Latson et al. | Jan 1999 | A |
5904703 | Gilson | May 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6174322 | Schneidt | Jan 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6238403 | Greene et al. | May 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6355051 | Sisskind et al. | Mar 2002 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6458100 | Roue et al. | Oct 2002 | B2 |
6488689 | Kaplan et al. | Dec 2002 | B1 |
6530934 | Jacobsen et al. | Mar 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6561969 | Frazier et al. | May 2003 | B2 |
6641557 | Frazier et al. | Nov 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6666861 | Grabek | Dec 2003 | B1 |
6689150 | VanTassel et al. | Feb 2004 | B1 |
6702825 | Frazier et al. | Mar 2004 | B2 |
6706065 | Langberg et al. | Mar 2004 | B2 |
6712804 | Roue et al. | Mar 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6746472 | Frazier et al. | Jun 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6979344 | Jones et al. | Dec 2005 | B2 |
6994092 | van der Burg et al. | Feb 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7014645 | Greene, Jr. et al. | Mar 2006 | B2 |
7025756 | Frazier et al. | Apr 2006 | B2 |
7044134 | Khairkhahan et al. | May 2006 | B2 |
7056294 | Khairkhahan et al. | Jun 2006 | B2 |
7115110 | Frazier et al. | Oct 2006 | B2 |
7128073 | van der Burg et al. | Oct 2006 | B1 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7169164 | Borillo et al. | Jan 2007 | B2 |
7192439 | Khairkhahan et al. | Mar 2007 | B2 |
7226458 | Kaplan et al. | Jun 2007 | B2 |
7293562 | Malecki et al. | Nov 2007 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7608091 | Goldfarb et al. | Oct 2009 | B2 |
7717937 | Wahr et al. | May 2010 | B2 |
7727189 | Van Tassel et al. | Jun 2010 | B2 |
7780645 | Jones | Aug 2010 | B2 |
7842054 | Greene, Jr. et al. | Nov 2010 | B2 |
8142470 | Quinn et al. | Mar 2012 | B2 |
8740934 | McGuckin, Jr. | Jun 2014 | B2 |
20010003161 | Vardi et al. | Jun 2001 | A1 |
20020026094 | Roth | Feb 2002 | A1 |
20020026217 | Baker et al. | Feb 2002 | A1 |
20020062130 | Jugenheimer et al. | May 2002 | A1 |
20020177855 | Greene, Jr. et al. | Nov 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20030014075 | Rosenbluth et al. | Jan 2003 | A1 |
20030055455 | Yang et al. | Mar 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030120337 | Van Tassel et al. | Jun 2003 | A1 |
20030125790 | Fastovsky et al. | Jul 2003 | A1 |
20030171739 | Murphy et al. | Sep 2003 | A1 |
20030181942 | Sutton et al. | Sep 2003 | A1 |
20030187474 | Keegan et al. | Oct 2003 | A1 |
20030191526 | Van Tassel et al. | Oct 2003 | A1 |
20030195555 | Khairkhahan et al. | Oct 2003 | A1 |
20030199923 | Khairkhahan et al. | Oct 2003 | A1 |
20030204203 | Khairkhahan et al. | Oct 2003 | A1 |
20030212432 | Khairkhahan et al. | Nov 2003 | A1 |
20030220667 | van der Burg et al. | Nov 2003 | A1 |
20040034366 | van der Burg et al. | Feb 2004 | A1 |
20040122467 | VanTassel et al. | Jun 2004 | A1 |
20040127935 | VanTassel et al. | Jul 2004 | A1 |
20040215230 | Frazier et al. | Oct 2004 | A1 |
20040260317 | Bloom et al. | Dec 2004 | A1 |
20040267191 | Gifford, III et al. | Dec 2004 | A1 |
20050004652 | van der Burg et al. | Jan 2005 | A1 |
20050033409 | Burke et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050049573 | Van Tassel et al. | Mar 2005 | A1 |
20050060017 | Fischell et al. | Mar 2005 | A1 |
20050065589 | Schneider et al. | Mar 2005 | A1 |
20050075665 | Brenzel et al. | Apr 2005 | A1 |
20050090860 | Paprocki | Apr 2005 | A1 |
20050113861 | Corcoran et al. | May 2005 | A1 |
20050192616 | Callister et al. | Sep 2005 | A1 |
20050192627 | Whisenant et al. | Sep 2005 | A1 |
20050234540 | Peavey | Oct 2005 | A1 |
20050234543 | Glaser | Oct 2005 | A1 |
20050256532 | Nayak et al. | Nov 2005 | A1 |
20050267524 | Chanduszko | Dec 2005 | A1 |
20060009798 | Callister | Jan 2006 | A1 |
20060009800 | Christianson et al. | Jan 2006 | A1 |
20060036282 | Wahr et al. | Feb 2006 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060122646 | Corcoran et al. | Jun 2006 | A1 |
20060149299 | Greene et al. | Jul 2006 | A1 |
20060149307 | Durgin | Jul 2006 | A1 |
20060149314 | Borillo et al. | Jul 2006 | A1 |
20060206148 | Khairkhahan et al. | Sep 2006 | A1 |
20060217761 | Opolski | Sep 2006 | A1 |
20060276839 | McGuckin, Jr. | Dec 2006 | A1 |
20070083230 | Javois | Apr 2007 | A1 |
20070083232 | Lee | Apr 2007 | A1 |
20070088388 | Opolski et al. | Apr 2007 | A1 |
20070112382 | Thill et al. | May 2007 | A1 |
20070123934 | Whisenant et al. | May 2007 | A1 |
20070129757 | Armstrong | Jun 2007 | A1 |
20070173885 | Cartier et al. | Jul 2007 | A1 |
20070179527 | Eskuri et al. | Aug 2007 | A1 |
20070179583 | Goetzinger et al. | Aug 2007 | A1 |
20070191884 | Eskridge et al. | Aug 2007 | A1 |
20070198059 | Patel et al. | Aug 2007 | A1 |
20070237720 | Padilla et al. | Oct 2007 | A1 |
20070276415 | Kladakis et al. | Nov 2007 | A1 |
20080039929 | Davis et al. | Feb 2008 | A1 |
20080119891 | Miles et al. | May 2008 | A1 |
20080215086 | Olsen et al. | Sep 2008 | A1 |
20090025820 | Adams | Jan 2009 | A1 |
20090069840 | Hallisey | Mar 2009 | A1 |
20090099596 | McGuckin, Jr. et al. | Apr 2009 | A1 |
20090112249 | Miles et al. | Apr 2009 | A1 |
20090318948 | Linder et al. | Dec 2009 | A1 |
20100228279 | Miles et al. | Sep 2010 | A1 |
20100228285 | Miles et al. | Sep 2010 | A1 |
20100234878 | Hruska et al. | Sep 2010 | A1 |
20100324585 | Miles et al. | Dec 2010 | A1 |
20100324586 | Miles et al. | Dec 2010 | A1 |
20100324587 | Miles et al. | Dec 2010 | A1 |
20100324588 | Miles et al. | Dec 2010 | A1 |
20110022079 | Miles et al. | Jan 2011 | A1 |
20110046658 | Connor et al. | Feb 2011 | A1 |
20110054515 | Bridgeman et al. | Mar 2011 | A1 |
20110208233 | McGuckin, Jr. et al. | Aug 2011 | A1 |
20120316584 | Miles et al. | Dec 2012 | A1 |
Number | Date | Country |
---|---|---|
102006056283 | Jun 2008 | DE |
1266630 | Dec 2002 | EP |
1358850 | Nov 2003 | EP |
1523957 | Apr 2005 | EP |
1741393 | Jan 2007 | EP |
9933402 | Jul 1999 | WO |
0027292 | May 2000 | WO |
0193920 | Dec 2001 | WO |
02071977 | Sep 2002 | WO |
03028802 | Apr 2003 | WO |
2004045393 | Jun 2004 | WO |
2005053547 | Jun 2005 | WO |
2005099365 | Oct 2005 | WO |
2006033641 | Mar 2006 | WO |
2006047748 | May 2006 | WO |
2007054116 | May 2007 | WO |
2007147145 | Dec 2007 | WO |
2010081033 | Jul 2010 | WO |
2010148246 | Dec 2010 | WO |
Entry |
---|
International Search Report dated Jun. 15, 2009, for International Application No. PCT/US2008/080374 (7 pages). |
International Search Report and Written Opinion dated May 6, 2010, for International Application No. PCT/US2010/020539 (12 pages). |
International Search Report and Written Opinion dated May 7, 2010, for International Application No. PCT/US2010/020547 (10 pages). |
International Search Report and Written Opinion dated Apr. 26, 2010, for International Application No. PCT/US2010/020549 (16 pages). |
Number | Date | Country | |
---|---|---|---|
20090112249 A1 | Apr 2009 | US |
Number | Date | Country | |
---|---|---|---|
60981451 | Oct 2007 | US | |
61047058 | Apr 2008 | US |